A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease

Vichinsky, E; Hoppe, CC; Ataga, KI; Ware, RE; Nduba, V; El-Beshlawy, A; Hassab, H; Achebe, MM; Alkindi, S; Brown, RC; Diuguid, DL; Telfer, P; Tsitsikas, DA; Elghandour, A; Gordeuk, VR; Kanter, J; Abboud, MR; Lehrer-Graiwer, J; Tonda, M; Intondi, A; T

Vichinsky, E (reprint author), Univ Calif San Francisco, Benioff Childrens Hosp Oakland, 747 52nd St, Oakland, CA 94609 USA.

NEW ENGLAND JOURNAL OF MEDICINE, 2019; 381 (6): 509

Abstract

In a trial evaluating two daily-dose levels of voxelotor, which binds to sickle hemoglobin and prevents polymerization under hypoxic conditions, hemog......

Full Text Link